Axiom Investment Management LLC Invests $868,000 in Merck & Co., Inc. $MRK

Axiom Investment Management LLC acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 7,217 shares of the company’s stock, valued at approximately $868,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Chesapeake Wealth Management boosted its holdings in Merck & Co., Inc. by 0.6% in the fourth quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock worth $1,552,000 after acquiring an additional 87 shares in the last quarter. South Plains Financial Inc. grew its stake in shares of Merck & Co., Inc. by 0.6% during the fourth quarter. South Plains Financial Inc. now owns 15,535 shares of the company’s stock worth $1,635,000 after acquiring an additional 89 shares during the last quarter. Syverson Strege & Co increased its holdings in shares of Merck & Co., Inc. by 2.2% during the fourth quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock valued at $436,000 after acquiring an additional 90 shares in the last quarter. Nations Financial Group Inc. IA ADV increased its holdings in shares of Merck & Co., Inc. by 0.4% during the first quarter. Nations Financial Group Inc. IA ADV now owns 23,433 shares of the company’s stock valued at $2,819,000 after acquiring an additional 91 shares in the last quarter. Finally, Westside Investment Management Inc. raised its position in shares of Merck & Co., Inc. by 3.1% in the 4th quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock valued at $331,000 after purchasing an additional 93 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Scotiabank lifted their target price on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, June 30th. Guggenheim upped their price target on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Wall Street Zen lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. BMO Capital Markets raised their price target on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Finally, Citigroup began coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price objective for the company. Thirteen research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $134.50.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s launch of subcutaneous Keytruda, known as Qlex, and other lifecycle extensions could preserve the drug’s commercial momentum and support exclusivity through 2039. Recent regulatory approvals, pipeline progress and the acquisitions of Terns and Cidara also broaden the company’s oncology and virology prospects. Merck: Heading Into Q2 Earnings, The Keytruda Cliff Looks Increasingly Less Steep
• Positive Sentiment: Analyst estimates have improved, including Erste Group’s modest increase in its FY2027 EPS forecast to $9.54 from $9.52. Barclays has also forecast strong potential appreciation for MRK, reinforcing the constructive sentiment around the shares. Barclays Forecasts Strong Price Appreciation for Merck & Co., Inc. Stock
• Positive Sentiment: Merck declared a quarterly dividend of $0.85 per share, payable October 7 to shareholders of record September 15. The dividend provides ongoing income support, with a reported annualized yield of about 2.6%.
• Neutral Sentiment: MRK is scheduled to release second-quarter 2026 results before the market opens on August 4. Consensus calls for approximately $16.33 billion in sales and a loss of $0.26 per share, with acquisition costs likely affecting reported earnings. Investors will watch Keytruda demand, Gardasil performance and management’s outlook. Should You Buy, Sell or Hold Merck Stock Ahead of Q2 Earnings?
• Neutral Sentiment: Merck and Wellcome’s Hilleman Laboratories are preparing an experimental Ebola vaccine for clinical trials. The initiative supports Merck’s public-health profile but is unlikely to materially affect near-term financial results. Merck, Wellcome Partner With Global Health Group to Make Ebola Vaccine for Clinical Trials
• Negative Sentiment: After a roughly 17% rally since its latest quarterly results, MRK may already reflect much of the favorable Keytruda and pipeline news. Analysts characterize its longer-term valuation as justified rather than clearly inexpensive, while Gardasil weakness and the approaching earnings event remain risks. Merck Stock Looks Cheap on Cash Flow but Fair on Earnings

Merck & Co., Inc. Trading Up 0.5%

Shares of NYSE:MRK opened at $130.49 on Friday. Merck & Co., Inc. has a 52-week low of $77.53 and a 52-week high of $135.05. The stock has a market cap of $322.28 billion, a price-to-earnings ratio of 36.76, a PEG ratio of 5.15 and a beta of 0.19. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The business has a 50-day moving average price of $123.17 and a 200-day moving average price of $118.46.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The firm had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company’s revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.22 earnings per share. Equities analysts predict that Merck & Co., Inc. will post 2.74 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.6%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is presently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.